Testicular Cancer Clinical Trial
Official title:
A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen
The incidence of testicular germ cell tumors (TGCT) has increased during the twentieth
century and is of particular concern as it primarily affects young men. It is the most common
cancer among U.S. males ages 25-34. The only well-described risk factors are cryptorchism
(undescended testis), family history of TGCT, and personal history of TGCT. To better
understand the environmental and genetic determinants of TGCT risk, a case-control study will
be conducted among members of the U.S. armed forces. The study will include men who have
donated a blood sample to the Department of Defense Serum Repository (DoDSR) between 1989 and
2000. All DoDSR donors who have developed GCT will be matched to DoDSR donors who have not
developed TGCT. Approximately 1,080 men with TGCT, 1,080 controls, and 2,160 mothers will be
included in the study.
The DoDSR serum sample will be tested for organochlorines levels, gonadotropin levels, and
viral antibody titres. Each participant will donate a saliva specimen that will be used in an
examination of genetic susceptibility. Each participant will also complete a questionnaire
concerning a variety of possible risk factors such as physical activity, medical history,
medication history, and other risk factors. The mothers of all participants will be invited
to participate by completing a questionnaire concerning perinatal exposures and events and by
donating a saliva sample.
The three main objectives of this study are to:
- determine whether environmental endocrine modulators (i.e., chlorinated pesticides and
polychlorinated biphenyls) are related to risk of GCT and, if so, whether their effects
are augmented by other risk factors.
- determine whether genetic susceptibility to GCT exists and to characterize the
environmental risk factors related to that susceptibility.
- determine whether there are distinct causes of GCT by relating the tissue structures of
the tumors to the risk factors.
The incidence of testicular germ cell tumors (TGCT) has increased during the better part of
the twentieth century and is of particular concern as it primarily affects young men. Though
the tumor is relatively infrequent in the population as a whole, TGCT is the most common
cancer among U.S. males in the age group 15-34 years. Despite the increases in TGCT rates,
the etiology is still poorly understood. The only well described risk factors for TGCT are
cryptorchism, family history of TGCT and personal history of TGCT. Therefore, in order to
understand better the environmental and genetic determinants of TGCT risk, a case-control
study will be conducted among members of the U.S. Armed Forces. The study will include men
who have donated a blood sample to the Department of Defense Serum Repository (DoDSR) between
the years 1989 and 2003. All DoDSR donors who have developed GCT will be matched to DoDSR
donors who have not developed TGCT.
A total of 1682 servicemen were enrolled in the study; 754 cases and 928 controls. Of these
participants, 1303 men (77%, 590 cases, 713 controls) donated buccal cell samples. In
addition to the servicemen, a total of 1090 mothers of servicemen were enrolled and 952 (87%)
provided a buccal specimen. The DoDSR serum samples have been assayed for levels of
organochlorines pesticides, polychlorinated biphenyl congeners, insulin-like growth factors
and gonadotropins and steroid hormones. DNA isolated from the buccal cell specimens have thus
far been genotyped for polymorphysms in the hormone metabolism and immune function pathway,
immune function pathway, insulin-like growth factor pathway and for single nucleotide
polymorphisms in the 8q24 locus. In addition, a genome-wide association study has completed.
Statistical analyses of the questionnaire data are continuing.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00772694 -
Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy
|
Phase 2 | |
Completed |
NCT00705094 -
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients
|
N/A | |
Terminated |
NCT00531687 -
Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer
|
Phase 2 | |
Terminated |
NCT00820287 -
Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk
|
N/A | |
Completed |
NCT00216801 -
Relationship of Ochratoxin A to Upper Urologic Cancers
|
N/A | |
Active, not recruiting |
NCT03142802 -
Low-Dose CT - Stage I Testicular Cancer
|
N/A | |
Recruiting |
NCT03232541 -
The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting
|
N/A | |
Completed |
NCT03557177 -
Clinical Characterisation of the Vascular Effects of Cis-platinum Based Chemotherapy in Patients With Testicular Cancer
|
||
Active, not recruiting |
NCT01783145 -
Shared Care Follow-up After Chemotherapy for Testicular Cancer
|
||
Recruiting |
NCT05611307 -
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
|
||
Completed |
NCT02573584 -
Vascular Fingerprint Validation Study
|
||
Recruiting |
NCT05670938 -
Follow-up After Surgery for Testicular Cancer
|
||
Recruiting |
NCT02994758 -
Development of Diagnostics and Treatment of Urological Cancers
|
N/A | |
Completed |
NCT02991209 -
Study of Testosterone vs Placebo in Testicular Cancer Survivors
|
Phase 2/Phase 3 | |
Completed |
NCT02602041 -
Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners; A Pilot Study
|
||
Completed |
NCT02092740 -
REtrospective Study of TESTIcular CAncer Patients at the University Magdeburg
|
N/A | |
Completed |
NCT01482741 -
Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging
|
N/A | |
Active, not recruiting |
NCT01242072 -
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
|
Phase 1 | |
Completed |
NCT01242631 -
Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
|
Phase 2 | |
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A |